Repaglinide
Prandin, NovoNorm (repaglinide) is a small molecule pharmaceutical. Repaglinide was first approved as Prandin on 1997-12-22. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against ATP-binding cassette sub-family C member 8.
| Trade Name | NovoNorm, Prandin |
|---|---|
| Common Name | Repaglinide |
| Indication | type 2 diabetes mellitus |
| Drug Class | Antidiabetic, SGLT2 inhibitors, not phlorozin derivatives |
